TEPEZZA
US Stocks: Viridian shares plunge 34% as eye disease drug disappoints on efficacy despite trial successViridian Therapeutics shares slumped 34% to an eight-month low on Monday after its experimental treatment for thyroid eye disease lagged ri...
- Load More